Prenatal diagnosis of sickle cell disease by amniocentesis using FTA technology in a context of precariousness in sub-Saharan Africa: Challenges and perspectives

This study demonstrates that FTA Elute technology enables reliable, rapid, and cost-effective prenatal diagnosis of sickle cell disease via amniocentesis in resource-limited settings like Kinshasa, while also characterizing the socioeconomic and genetic profiles of the couples seeking these services.

The Gist

Imagine a world where a genetic "glitch" in your blood causes it to get stuck like a clogged drain, leading to severe pain and early death. This is Sickle Cell Disease (SCD). In many parts of Africa, this glitch is very common. While there are treatments to help manage the pain, there is no easy "cure-all" pill available for everyone yet. The best way to stop the suffering is to prevent the disease from being passed down to children in the first place.

This paper is a story about how a team of scientists in Kinshasa, Democratic Republic of Congo, figured out a clever, low-cost way to check a baby's blood before it's born, even in a place where money and fancy equipment are scarce.

Here is the breakdown of their journey, explained simply:

1. The Problem: The "Expensive" Test

Usually, to check if a baby has Sickle Cell Disease before birth, doctors have to take a tiny sample of the fluid surrounding the baby (amniocentesis). Then, they have to run a complex lab test to find the genetic "glitch."

Think of the old way like trying to bake a cake in a kitchen with no oven, no mixer, and no electricity. You have to mix the ingredients by hand for 8 hours, keep everything in a freezer (a "cold chain") so it doesn't spoil, and wait two days to see if the cake is ready. In poor countries, this is too hard, too slow, and too expensive.

2. The Solution: The "Magic Paper" (FTA Elute)

The researchers decided to try a new tool called FTA Elute technology.

Imagine the FTA card as a special piece of paper that acts like a sponge and a shield at the same time.

• The Sponge: When you drop a drop of the baby's fluid onto this paper, it instantly soaks up the cells and breaks them open to get the DNA (the genetic instructions) out.
• The Shield: It traps the "bad stuff" (germs and chemicals that mess up tests) inside the paper fibers, keeping the DNA safe and clean.

The Magic Trick:
Instead of spending 8 hours in a lab mixing chemicals, you just let the paper dry on a shelf. You don't need a freezer. You don't need a fancy lab. You can mail this paper in a regular envelope! When the lab is ready, they just wash the paper with water, and the clean DNA comes out, ready to be tested. It's like going from baking a cake by hand for 8 hours to using a microwave that takes 30 seconds.

3. The Experiment: Who Asked for the Test?

The team tested this method on 107 couples in Kinshasa. These were parents who already had one child with Sickle Cell Disease and were worried about having another.

• Who were they? Most were young parents (average age 28). Interestingly, the study found that many of these parents were actually doing quite well financially (middle class or elite), likely because they had the money and education to know they needed this test.
• The Results:
  • 77% of the babies were "carriers" (like the parents). They have the gene but won't get sick.
  • 14% were completely free of the gene.
  • 9% had the disease (Sickle Cell).
  • Safety: The procedure was very safe. Only one pregnancy ended in tragedy, but the doctors found out it was due to severe malaria and infection, not because of the test itself.

4. Why This Matters: The "Game Changer"

The researchers compared their "Magic Paper" method to the expensive, standard commercial kits.

• Speed: The old way took 2 days. The new way took less than 24 hours.
• Cost: The paper is much cheaper than the expensive chemical kits.
• Logistics: The old way needed a freezer truck to move samples. The new way can be mailed in the post.

The Big Picture

This study is like finding a bicycle in a world where everyone is trying to drive a Ferrari to get to the hospital. The Ferrari (standard lab tests) is great if you have money and a smooth road, but in a place with potholes and no gas stations (resource-limited settings), the bicycle (FTA Elute) gets you there faster, cheaper, and without breaking down.

The Conclusion:
The scientists proved that you don't need a high-tech, expensive lab to save babies from Sickle Cell Disease. By using this simple, "magic paper" technology, countries with fewer resources can screen unborn babies quickly and affordably. This gives parents the power to make informed choices and, hopefully, stop the cycle of suffering for the next generation.

Technical Summary

1. Problem Statement

Sickle Cell Disease (SCD) is the most prevalent inherited hemoglobinopathy globally, with 80% of new cases occurring in sub-Saharan Africa. In the Democratic Republic of Congo (DRC), the prevalence of the sickle cell trait is 25–35%, and homozygous SS individuals represent 1.7–2% of the population.

• Clinical Burden: SCD causes high early mortality (40–55% before age 5) and significant morbidity.
• Therapeutic Limitations: Curative treatments (bone marrow transplant, stem cell therapy) are inaccessible in resource-limited settings. Hydroxyurea, the only effective drug, is often unavailable.
• Diagnostic Gap: While early diagnosis (neonatal or prenatal) is crucial for management, conventional prenatal molecular diagnosis relies on complex, time-consuming, and expensive DNA extraction methods (e.g., salting-out) requiring cold chains and specialized equipment. These barriers make prenatal screening inaccessible for many in low-resource settings.

2. Methodology

Study Design and Population:

• Type: Cross-sectional study conducted from January 2020 to December 2025.
• Location: Kinshasa, DRC (Sickle Cell Center and University Hospital of Kinshasa).
• Participants: 107 couples requesting prenatal diagnosis. All couples had at least one child with SCD.
• Inclusion: Pregnant women referred by physicians or via genetic counseling who provided informed consent.

Diagnostic Protocol:

1. Sample Collection: Amniocentesis was performed between the 16th and 17th weeks of amenorrhea to collect 15 ml of amniotic fluid.
2. FTA Elute Technology (Experimental):
   • Amniotic fluid was centrifuged (3500 rpm, 30 min).
   • Sediment was resuspended in PCR water, and 40 µl was spotted onto FTA Elute cards.
   • Cards were air-dried at room temperature.
   • Elution: A 1.2 mm punch was cut from the card, washed with 500 µl PCR water, and vortexed to release DNA. This process took 30 minutes.
   • PCR: The eluted DNA was used directly for PCR amplification of a 440 bp fragment of the HBB gene.
   • Genotyping: PCR-RFLP (Restriction Fragment Length Polymorphism) using the DdeI restriction enzyme.
     • AA (Normal): 3 bands (72, 167, 201 bp).
     • AS (Carrier): 4 bands (72, 167, 201, 368 bp).
     • SS (Disease): 2 bands (72, 368 bp).
3. Validation (Gold Standard): Postnatal confirmation was performed on umbilical cord blood using the conventional salting-out technique (6–8 hours extraction time) followed by the same PCR-RFLP analysis.

Data Analysis:

• Demographic and socioeconomic data were collected. Socioeconomic status was categorized into five classes (Elite to Precarious).
• Genotype frequencies and pregnancy outcomes were analyzed using descriptive statistics.

3. Key Contributions

• First Application in Sub-Saharan Africa: This is the first study to utilize FTA Elute technology for prenatal SCD diagnosis in a resource-limited African setting.
• Feasibility in Precarious Contexts: The study demonstrates that high-quality molecular diagnosis is achievable without expensive infrastructure, cold chains, or prolonged processing times.
• Socioeconomic Profiling: It provides a detailed profile of the couples seeking prenatal diagnosis in Kinshasa, highlighting that the majority belong to the upper-middle and lower-middle classes, suggesting that cost and awareness remain barriers for the poorest populations.

4. Key Results

Demographics and Socioeconomics:

• Maternal Age: Mean 28 ± 4 years.
• Genotype Awareness: 76.6% of couples knew their AS status pre-marriage; 10.2% discovered it after the birth of an affected child; 13.0% were high-risk couples (SS x AS).
• Socioeconomic Status: 39.2% Upper Middle Class, 36.4% Lower Middle Class, 5.6% Elite. Only a small fraction fell into the "precarious" class, indicating that current prenatal services are not yet reaching the most impoverished.

Diagnostic Performance:

• Fetal Genotypes:
  • AS (Heterozygous): 77% (82 fetuses).
  • AA (Homozygous Normal): 14% (15 fetuses).
  • SS (Homozygous SCD): 9% (10 fetuses).
• Accuracy: 100% concordance between the FTA Elute prenatal results and the postnatal salting-out confirmation.
• Turnaround Time: Results were available in <24 hours using FTA Elute, compared to 48+ hours for conventional methods.

Safety and Cost-Effectiveness:

• Pregnancy Outcomes: 99% live births; 1% intrauterine fetal death (attributed to maternal malaria and UTI, not the procedure).
• Technical Advantages:
  • Time: DNA extraction reduced from 6–8 hours to 30 minutes.
  • Storage/Transport: Eliminated the need for a cold chain; samples can be mailed at room temperature.
  • Cost: Significantly lower reagent costs compared to commercial kits.
  • Safety: Reduced biohazard risk and contamination potential.

5. Significance and Conclusion

The study validates FTA Elute technology as a robust, reliable, and cost-effective alternative to conventional DNA extraction for prenatal SCD diagnosis in low-resource settings.

• Public Health Impact: By reducing turnaround time and eliminating the cold chain requirement, this technology makes prenatal screening logistically feasible in remote or underfunded regions of sub-Saharan Africa.
• Strategic Recommendation: The authors advocate for the widespread adoption of FTA Elute technology in national screening programs to reduce the birth prevalence of SCD. They emphasize that while the technology is accessible, broader implementation requires addressing socioeconomic barriers to ensure the "precarious" class can also access these life-saving diagnostics.
• Future Outlook: The study suggests that integrating this simplified molecular workflow into routine obstetric care in the DRC and similar contexts is a critical step toward reducing SCD-related mortality and morbidity.